Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Graft Polymer (UK) PLC ( (GB:SVNS) ) just unveiled an announcement.
Solvonis Therapeutics announced that its CEO, Anthony Tennyson, will present at the PharmaSynergyRx 2025 event in London, highlighting the company’s strategic growth in the biotechnology sector. This event, which gathers over 200 industry executives, offers a platform for Solvonis to pursue co-developments, partnerships, and commercial deals, potentially enhancing its market position and stakeholder value.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is an innovative biotechnology company focused on developing intellectual property related to the treatment of mental health and substance use disorders. The company co-develops therapeutics for mental health disorders, with an initial focus on trauma-related conditions such as PTSD, which affected approximately 13 million adults in the U.S. in 2020. Solvonis estimates a current affected population of 20 million across the U.S., UK, and key EU markets.
YTD Price Performance: -14.63%
Average Trading Volume: 17,321,193
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £4.02M
See more data about SVNS stock on TipRanks’ Stock Analysis page.